Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

BioInvent International

38.05

 

SEK

 

+0.66 %

Less than 1K followers

BINV

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus

BioInvent International is a biotechnology company focused on the development of innovative antibody therapies for cancer treatment. The company researches new treatments that can improve patient outcomes and quality of life. The company operates globally with a presence in international markets. BioInvent International was founded in 1983 and is headquartered in Lund.

Read more
Market cap
2.5B SEK
Turnover
3.34M SEK
Revenue
44.69M
EBIT %
-1,054.06 %
P/E
-
Dividend yield-%
-
Financial calendar
26/8
2025

Interim report Q2'25

29/10
2025

Interim report Q3'25

All
Webcasts
Press releases
ShowingAll content types
Regulatory press release9 hours ago

BioInvent presenterar lovande fas 2a-monoterapidata för BI-1808 i CTCL på EHA 2025

BioInvent International
Regulatory press release9 hours ago

BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025

BioInvent International
Press release9 hours ago

BioStock: BioInvent fokuserar på första linjens behandling

BioInvent International

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release9 hours ago

BioStock: BioInvent focus on first line treatment

BioInvent International
Press releaseyesterday

BioInvent presenterar lovande fas 1-data för BI-1206 i kombination med KEYTRUDA® (pembrolizumab) i solida tumörer

BioInvent International
Press releaseyesterday

BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors

BioInvent International
Press release6/4/2025, 6:00 AM

BioInvent presenterar poster på PAGE 2025 som beskriver modellbaserad tidig klinisk utveckling av anti-TNFR2 läkemedelskandidaten BI-1910

BioInvent International
Press release6/4/2025, 6:00 AM

BioInvent Presents at PAGE 2025 a Poster Highlighting Model-Informed Early Clinical Development of anti-TNFR2 drug candidate BI-1910

BioInvent International
Press release6/2/2025, 12:58 PM

BioStock: BioInvent secured up to 30 MUSD from XOMA royalty

BioInvent International
Press release6/2/2025, 12:58 PM

BioStock: BioInvent säkrade upp till 30 MUSD från XOMA Royalty

BioInvent International
Press release5/28/2025, 6:21 AM

Investor Studios: BioInvents VD & CMO om bolaget, XOMA-affären och pågående studier

BioInvent International
Regulatory press release5/27/2025, 12:00 PM

XOMA Royalty förvärvar mezagitamab royalty- och milstolpsrättigheter av BioInvent International för upp till 30 miljoner USD

BioInvent International
Regulatory press release5/27/2025, 12:00 PM

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD 30 Million

BioInvent International
Regulatory press release5/14/2025, 1:30 PM

Uppdatering från BioInvents fas 2a-trippelkombinationsstudie med BI-1206, rituximab och Calquence för behandling av non-Hodgkins lymfom

BioInvent International
Regulatory press release5/14/2025, 1:30 PM

BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the treatment of non-Hodgkin's lymphoma

BioInvent International
Regulatory press release5/14/2025, 1:30 PM

BioInvent presenterar ytterligare fas 2a-data för BI-1808 monoterapi i CTCL på EHA 2025

BioInvent International
Regulatory press release5/14/2025, 1:30 PM

BioInvent Presents Additional CTCL Phase 2a Data for BI-1808 Monotherapy at EHA 2025

BioInvent International
Press release5/5/2025, 1:30 PM

BioInvent deltar i kommande investerarkonferenser

BioInvent International
Press release5/5/2025, 1:30 PM

BioInvent to Participate in Upcoming Investor Conferences

BioInvent International
Press release5/5/2025, 9:22 AM

BioInvent International AB: BioStock: BioInvent secures FDA Fast Track Designation for BI-1808

BioInvent International
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team